Gadolinium-based contrast agents (GBCAs) are contraindicated in patients with GFR <30 mL/min/1.73m² primarily due to risk of:

• A Contrast-induced nephropathy (CIN)
• B Anaphylaxis with bronchospasm
• C Gadolinium deposition disease in bone marrow
• D Nephrogenic systemic fibrosis (NSF) ✓

Explanation

Nephrogenic systemic fibrosis (NSF) is a debilitating fibrosing disorder affecting skin, joints, and viscera (lungs, heart, diaphragm), occurring almost exclusively in patients with severe renal impairment (GFR <30 mL/min) who received gadolinium-based contrast agents. Reduced GFR prolongs gadolinium retention, allowing transmetallation — Gd³⁺ dissociates from its chelate and deposits in tissues. Linear (non-macrocyclic) GBCAs carry highest risk (gadodiamide, gadopentetate). Macrocyclic GBCAs (gadobutrol, gadoterate) have negligible NSF risk. CIN is the risk from iodinated contrast, not gadolinium. Gadolinium deposition in brain (globus pallidus/dentate nucleus) occurs but is not the primary contraindication in renal failure.

Reference: Grainger & Allison's Diagnostic Radiology, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.